Skip to Content
Merck
All Photos(1)

Documents

670820

Sigma-Aldrich

Pam3-Cys-OH

≥98.0% (TLC), for peptide synthesis

Synonym(s):

N-α-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-L-cysteine, Palmitoyl-Cys((RS)-2,3-di(palmitoyloxy)-propyl)-OH

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C54H103NO7S
CAS Number:
87420-41-5
Molecular Weight:
910.46
MDL number:
MFCD00153468
UNSPSC Code:
12352209
eCl@ss:
32160406
PubChem Substance ID:
24885087
NACRES:
NA.22

product name

Pam3-Cys-OH, ≥98.0% (TLC)

Assay

≥98.0% (TLC)

reaction suitability

reaction type: solution phase peptide synthesis

application(s)

peptide synthesis

SMILES string

CCCCCCCCCCCCCCCC(=O)N[C@@H](CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(O)=O

InChI

1S/C54H103NO7S/c1-4-7-10-13-16-19-22-25-28-31-34-37-40-43-51(56)55-50(54(59)60)48-63-47-49(62-53(58)45-42-39-36-33-30-27-24-21-18-15-12-9-6-3)46-61-52(57)44-41-38-35-32-29-26-23-20-17-14-11-8-5-2/h49-50H,4-48H2,1-3H3,(H,55,56)(H,59,60)/t49?,50-/m0/s1

InChI key

PZFZLRNAOHUQPH-GOOVXGPGSA-N

Related Categories

General description

Pam3-Cys-OH is a lipopeptide containing a cysteine residue at the C-terminus, often used in solid phase peptide synthesis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Lipoconjugates for the noncovalent generation of microarrays in biochemical and cellular assays
A Hoff, et al.
Chembiochem, 3, 1183-1191 (2002)
Nishi Shakya et al.
Peptides, 32(10), 2131-2133 (2011-10-01)
Prophylactic potential of synthetic bacterial lipopeptide and a TLR2 agonist, Pam3Cys was first evaluated against experimental visceral leishmaniasis in rodent model. After establishing the potential its effect on therapeutic efficacy of miltefosine was also studied. Pam3Cys showed 74.64% inhibition in
Pitchaimani Kandasamy et al.
The Journal of biological chemistry, 286(10), 7841-7853 (2011-01-06)
Mycoplasma pneumoniae is a human pathogen causing respiratory infections that are also associated with serious exacerbations of chronic lung diseases. Membranes and lipoproteins from M. pneumoniae induced a 4-fold increase in arachidonic acid (AA) release from RAW264.7 and a 2-fold
Sudha Natarajan et al.
Shock (Augusta, Ga.), 33(2), 162-169 (2009-06-03)
LPS challenge causes potent activation of innate immunity. Because LPS is ubiquitously present in ambient air, repeated inhalation may lead to activation of the pulmonary immune response. If this activation is unregulated, chronic LPS inhalation would lead to persistent inflammation
Peter M Moyle et al.
Current medicinal chemistry, 15(5), 506-516 (2008-02-22)
Despite the important role of adjuvants for vaccine development, relatively few adjuvants have been successfully incorporated into vaccines intended for human administration. This is in part due to the high toxicity associated with many experimental adjuvants. This lack of choice
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service